ArticleOphthalmology2021

Re: Magone et al.: Ocular adverse effects of infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor (Ophthalmology. 2021;128:624-626).

Jasmine H Francis et al.PubMed ↗Publisher ↗

No numbers read from the abstract.